Active — Not RecruitingNot Applicable

Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL

Italy150 participantsStarted 2025-12-10

Plain-language summary

This study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024) * Received at least one dose of epcoritamab * Free and voluntary written informed consent Exclusion Criteria: * Age \< 18 years * Patients who received epcoritamab outside the Cnn program (e.g., open access program, compassionate use, off-label, prospective trials).

What they're measuring

Overall Response Rate (ORR)

Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Trial details

NCT IDNCT07393204

SponsorAndrés José Maria Ferreri

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-10

View on ClinicalTrials.gov More Relapsed Diffuse Large B-cell Lymphoma (DLBCL) trials